Evaluation of promoter hypermethylation in tissue and blood of non-small cell lung cancer patients and association with survival. Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018
Concordance of p53 and K-ras mutations in induced sputum and corresponding biopsies of patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 18s Year: 2001
Expression of ERCC1 in normal and tumor tissues in non-small cell lung cancer Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007
PD-L1 determination in cytological and histological samples in patients with non-small cell lung cancer Source: International Congress 2018 – Linear and radial EBUS and peripheral nodules Year: 2018
Clinical relevance of p53 and K-ras gene mutations in bronchial margins in surgically treated nonsmall cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002
Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011
p16INK4a promoter hypermethylation in tissue, blood, and sputum from non-small cell lung cancer and pulmonary inflammationSource: Eur Respir J 2006; 28: Suppl. 50, 813s Year: 2006
Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010
T790M-mutation in EGFR progressive non-small cell lung cancer, role of re-biopsy and ctDNA analysis Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017
ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009
Are there any peculiarities in tumour behavior and different tumour markers expression in nonsmall cell lung cancer? Source: Eur Respir J 2001; 18: Suppl. 33, 232s Year: 2001
Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007
Tumoural tissue specific promoter hypermethylation of distinct tumour suppressor genes in a case with nonsmall cell lung carcinoma: a case report Source: Annual Congress 2009 - Clinical aspects and epidemiology in lung cancer Year: 2009
Expression of βig-h3 as a marker of local tumor invasion in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 770s Year: 2006
Evaluation of serum tumour markers in the lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002
Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer Source: Annual Congress 2009 - Lung cancer biology Year: 2009
An analysis of EGFR expression and tumour imaging in non-small cell carcinomas of lung Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011
How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations Source: International Congress 2015 – How to treat brain metastases Year: 2015